Blood group antigens are either sugars or proteins found attached to the red blood cell membrane. ABO blood group antigens are the most clinically important antigens because they are the most immunogenic. As red blood cell antigens are inherited traits, they are usually not altered throughout the life of an individual. There have been occasional case reports of ABO blood group antigen change in malignant conditions. We report two such cases of ABO antigen alteration associated with acute myeloid leukemia. These patients had suppression of their blood group antigens during their leukemic phase, and the antigens were reexpressed when the patients attained remission. R ed blood cell (RBC) antigens are inherited traits and, as such, their expression is constant throughout the life of an individual. RBC antigen change has been occasionally described in association with hematological malignancies. Th ese modifi cations of blood group antigens usually revert to normal after remission is attained. We report two cases of patients with acute myeloid leukemia (AML) who had ABO antigen alteration during the acute leukemic phase and reexpression of their original ABO antigen upon remission.
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CASE DESCRIPTIONS
Two patients diagnosed with AML M5 (based on the French-American-British classifi cation) had discrepancy in their detected blood group by forward cross-matching; their clinical and laboratory features are summarized in the Table . Reverse cross-matching was done in the fi rst case, which failed to show the presence of anti-B antibodies. Reverse cross-matching revealed the presence of only anti-A antibodies. Elution and adsorption studies were performed. Th e patient's red cells were incubated with anti-B sera, followed by elution of adsorbed anti-B on her cells. Th e elute was then tested with group B and group O red cells for the presence of anti-B antibodies. Th e elute showed positive results with B red cells but a negative reaction with group O red cells, thus confi rming the presence of B antigen on the patient's RBC. Th e patient was started on 7 + 3 induction with cytarabine and daunorubicin, followed by consolidation with high-dose cytarabine. Th e strength of reaction of the patient's RBC with anti-B antibodies increased progressively with treatment. By the end of the second con-Blood group change in acute myeloid leukemia Rakul K. Nambiar , MD , Geetha Narayanan , MD, DM , N. P. Prakash , DM , and K. Vijayalakshmi , MD solidation, there was strong reaction with anti-B antibodies, and she regained her original blood group (B group). Th us, the original blood group B antigen was suppressed during the leukemic phase, and upon remission B antigens were reexpressed. Similarly in the second case, the original blood group B antigen was suppressed during the leukemic phase, and B antigens were reexpressed upon remission.
DISCUSSION
Loss or diminished expression of RBC antigens has been reported in both solid and hematological malignancies. ABO blood group antigen is the most commonly altered blood group antigen ( 1-4 ). For hematopoietic diseases, the loss of expression results predominantly from a mutation aff ecting antigen production in the stem cell. Complete or partial loss of antigen expression is seen among the progenitors of RBC arising from this aff ected stem cell, whereas the RBCs arising from unaff ected stem cells usually express normal RBC antigens. Loss or weakening of ABO antigens is usually detected as a discrepancy in the forward and reverse typing of patients. ABO antigens are the most frequently reported blood group antigen alteration because they are routinely tested for all patients before transfusion. A, B, and H antigens are formed from the same precursor substance. Th e production of ABO antigens depends on the functioning of two glycosyl transferases. Th e fi rst enzyme, H transferase, adds L-fucose to the terminal galactose of the precursor substance. Th e H substance is then acted on by the A or B transferases that add an N-acetyl galactosamine or a galactose, respectively. Th ere are two possible mechanisms for the weakening of ABO antigens in hematopoietic diseases. Th e fi rst mechanism is the inactivation of A/B transferases, and the second is the inactivation of H transferase. In the fi rst mechanism (5) (6) (7) (8) , there is decreased expression of the A and B antigens with a concurrent increase in H antigen. Th e H antigen is not converted to A and B antigen due to the inactivation of the A/B transferases. A and B transferase genes are encoded on chromosome 9, and they may be inactivated as a 9;22 chromosomal translocation. Th is is the plausible explanation for ABO alteration in CML. Th e second suggested mechanism for the loss of ABO antigens is inactivation of the H transferase encoded at 19q13 ( 9, 10 ) . H transferase inactivation would result in decreased H substance and a resulting decrease in A and/or B substance.
ABO antigen alterations are more commonly seen in AML, although a translocation involving chromosome 9 is seldom seen in AML. In a study of 12 AML patients with weakening of the ABO antigens, it was noted that ABO gene inactivation was not random ( 11 ) . In 4 of 12 patients studied, only the maternally derived A or B gene was noted to be aff ected, suggesting a possibility of genomic imprinting.
Loss and weakening of ABO antigens has also been reported prior to the diagnosis of an underlying hematopoietic malignancy. Th is is usually noted in the setting of myelodysplasia, where a patient with longstanding myelodysplasia has a blood group alteration and later manifests with AML ( 12, 13 ) . Th us, any loss of ABO antigens should culminate in the search for an underlying hematopoietic malignancy. Variations in ABO antigens may also refl ect the status of the malignancy. Upon remission, there is return of the original blood group, and with recurrence, there is suppression of blood group antigens ( 14 ) .
